Hims & Hers Health (NYSE:HIMS) Posts Quarterly Earnings Results, Beats Estimates By $0.26 EPS

Hims & Hers Health (NYSE:HIMS) issued its earnings results on Monday. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26, Briefing.com reports. The company had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 11.67%. The firm’s revenue for the quarter was up 77.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.04) earnings per share. Hims & Hers Health updated its Q4 2024 guidance to EPS and its FY 2024 guidance to EPS.

Hims & Hers Health Price Performance

Shares of NYSE HIMS traded up $0.69 during midday trading on Thursday, reaching $24.11. 4,182,585 shares of the stock traded hands, compared to its average volume of 8,598,200. The stock has a market capitalization of $5.18 billion, a PE ratio of 54.80 and a beta of 1.06. Hims & Hers Health has a one year low of $6.58 and a one year high of $25.74. The company’s 50 day moving average is $18.40 and its 200 day moving average is $18.29.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of research analyst reports. Truist Financial boosted their price objective on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. Bank of America boosted their price objective on shares of Hims & Hers Health from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Needham & Company LLC initiated coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price objective on the stock. TD Cowen boosted their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Finally, Canaccord Genuity Group boosted their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Insider Buying and Selling

In related news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28. Following the completion of the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at $487,789.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Soleil Boughton sold 2,339 shares of the firm’s stock in a transaction on Tuesday, October 29th. The stock was sold at an average price of $23.16, for a total transaction of $54,171.24. Following the transaction, the insider now owns 169,935 shares in the company, valued at approximately $3,935,694.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28. Following the transaction, the chief executive officer now owns 33,502 shares in the company, valued at approximately $487,789.12. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 650,659 shares of company stock worth $11,712,198 over the last three months. 17.71% of the stock is owned by insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.